Paper Details

  1. Home
  2. Paper Details

SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects.

Author: AndreucciMichele, BorrelliSilvio, ConteGiuseppe, De NicolaLuca, GarofaloCarlo, LibertiMaria Elena, MinutoloRoberto, ProvenzanoMichele

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Sodium-glucose cotransporter 2 inhibitors (SGLT2-i) are a new type of diabetes medication that can help lower blood sugar and protect the kidneys.
Paper Details　
Original Abstract of the Article :
The burden of diabetic kidney disease (DKD) has increased worldwide in the last two decades. Besides the growth of diabetic population, the main contributors to this phenomenon are the absence of novel nephroprotective drugs and the limited efficacy of those currently available, that is, the inhibit...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630922/

データ提供：米国国立医学図書館（NLM）

SGLT2 Inhibitors: A New Hope for Nephroprotection in Diabetic Kidney Disease

Diabetic kidney disease (DKD) is a major complication of diabetes, leading to kidney failure and requiring dialysis. This research explores the potential of sodium-glucose cotransporter 2 inhibitors (SGLT2-i) as nephroprotective agents in DKD. SGLT2-i are a class of drugs that lower blood glucose levels by inhibiting the reabsorption of glucose in the kidneys. Several recent clinical trials have demonstrated the efficacy of SGLT2-i in improving glycemic control and reducing cardiovascular risk in patients with type 2 diabetes. These trials also revealed positive effects on renal outcomes, such as glomerular filtration rate and albuminuria, suggesting that SGLT2-i may have nephroprotective properties.

SGLT2 Inhibitors: A Promising New Treatment for DKD

This research highlights the emerging role of SGLT2-i as a potential nephroprotective therapy for DKD. The positive effects observed in clinical trials suggest that SGLT2-i could significantly impact the management of DKD, slowing disease progression and improving outcomes for patients.

Navigating DKD: Exploring New Avenues for Treatment

This research underscores the importance of exploring new avenues for treating DKD, a condition with significant unmet medical needs. SGLT2-i offer a promising new approach to managing this complex disease, potentially leading to improved renal function and reduced risk of kidney failure.

Dr. Camel's Conclusion

Diabetic kidney disease can be a daunting desert, filled with the threat of kidney failure. This research offers a glimmer of hope in this arid landscape, highlighting the potential of SGLT2-i as a nephroprotective therapy. By inhibiting glucose reabsorption in the kidneys, these drugs could help protect renal function and slow disease progression. Let's continue to explore the potential of SGLT2-i and develop new strategies for treating DKD, ensuring that those navigating this challenging terrain can find relief and maintain their well-being.

Date :
  1. Date Completed 2019-12-19
  2. Date Revised 2020-02-25
Further Info :

Pubmed ID

31212638

DOI: Digital Object Identifier

PMC6630922

Related Literature

Article Analysis
・Side Effects of canagliflozin
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.